Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Phico Therapeutics Ltd.. (8/1/18). "Press Release: Phico Therapeutics Awarded Innovate UK Funding for £1.4 Million ($1.87M) Antibacterial Therapy Project". Cambridge.

Region Region United Kingdom (GB)
Organisations Organisation Phico Therapeutics Ltd.
  Organisation 2 Innovate UK
  Group United Kingdom (GB) (govt)
Products Product SASPject PT3.8
  Product 2 business development (state/region)
Index term Index term Phico Therapeutics–United Kingdom (govt): grant, 201808 Innovate UK grant £1.4m for developm of manufacturing of SASPject PT3.8 w TCTC + GE Heatlhcare
Persons Person Fairhead, Heather (Phico Therapeutics 201808 CEO)
  Person 2 Cuddon, Lorna (Zyme Communications 201007– Managing Director + Founder before College Hill Life Sciences)
     


Funding will support development of a Pseudomonas aeruginosa targeted therapeutic, to tackle the genetic cause of antibiotic resistance


Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing a novel platform technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced that it had been awarded significant funding to support the manufacturing development of its intravenous antibiotic, SASPject PT3.8. Innovate UK, the UK’s innovation agency, will provide £1.4 million ($1.87 million USD) to support the project, which will be undertaken in partnership with The Clinical Trial Company and GE Healthcare.

Phico is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate. P. aeruginosa causes a wide range of infections, most frequently in hospitals, and is very difficult to treat, due to the organisms/bacteria’s intrinsic antibiotic resistance mechanisms, including an impermeable cell membrane and efflux pumps, which can remove antibiotics that do enter the cell. As clinical trials are expanded, it is anticipated that the product will also be used in situations where a P. aeruginosa infection is suspected but yet to be confirmed, further extending the market opportunity for SASPject PT3.8.

SASPject PT3.8 has been developed using Phico’s SASPject™ platform, which utilises a unique antibacterial small acid-soluble spore proteins (SASP), to target and deactivate bacterial DNA, stopping bacteria from metabolising or reproducing. The Innovate UK funding will be used to improve the manufacturing yield of PT3.8. This includes the manufacture of a 15 litre pre-GMP batch for formal pre-clinical testing, and development of a quality management system (QMS) for manufacturing at Phico. As partners in the project, The Clinical Trial Company is developing the QMS and GE Healthcare advising on practical manufacturing processes. The programme cost will total £2 million ($2.65 million USD), and the remaining funds will provided by Phico’s shareholders.

Dr Heather Fairhead, CEO at Phico, said: “Our goal is to advance the science of antibacterial therapy to help overcome the global problem of bacterial resistance. This non-dilutive funding from Innovate UK is an important validation of our platform, and will enable us to take our lead product towards testing in humans.”

ENDS

About Phico Therapeutics Ltd http://www.phicotx.co.uk/


Contacts

Phico Therapeutics
Lorna Cuddon
Tel: +44 (0)7811996942
E-mail: lorna.cuddon@zymecommunications.com

   
Record changed: 2018-08-04

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top